Navin Fluorine Q2 FY27 Earnings Call: Solstice Contract Extended to December 2032, Revenue Jumps 57% YoY (NAVINFLUOR)

Navin Fluorine International Ltd held its Q2 FY27 earnings call on October 30, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Broad-Based Beat Across P&L, Margins Hold at 34.2%

• Q2 FY27 revenue of Rs.1,191 crore, up 57% YoY — operating EBITDA grew 66% YoY to Rs.407 crore with margins at 34.2%; operating PBT rose 87% to Rs.336 crore and PAT rose 81% to Rs.269 crore.
• H1 FY27 revenue up 51% YoY to Rs.2,236 crore — EBITDA grew 69% to Rs.765 crore with margins expanding 367 bps to 34.2%; PBT and PAT both rose 93% to Rs.619 crore and Rs.513 crore respectively.
• H1 FY27 PAT crossed Rs.500 crore with EPS of Rs.100 — board declared an interim dividend of Rs.8 per equity share (face value Rs.2).
• Net operating working capital at 72 days in H1 FY27 — within the company's financial framework.
• Gross profit held despite inflation — per EBITDA bridges, forex tailwind plus pricing actions largely offset sourcing impacts, aided by operating leverage; CFO cautioned the company is not yet out of geopolitical headwinds.
• 34% EBITDA margin called "solid" in the current cost environment — management attributed it to continuous efficiencies and internal improvements rather than pricing alone; HF price increases are accompanied by rises in sulfur, gas, other raw materials and power.

HPP, Specialty and CDMO All Deliver in Q2

• HPP posted healthy Q2 FY27 revenue growth — on higher volumes and improved realizations; HFC pricing environment remains firm with sequential realization improvement, and the new AHF facility saw improved utilization.
• QoQ HPP growth driven by better ref pricing and new HF plant volumes — plus QoQ growth in the Orchid business and the Solstice HFO business; HF merchant sales running "far larger" than previously indicated, with some volumes going to international markets and high-pure HF.
• Specialty chemicals reiterated as a Rs.350 crore run-rate business — guidance maintained over the last three quarters and playing out in FY 2026-2027; growth from more campaigns in the same MPP plants via product mapping and step minimization; strong order visibility for H2 FY27 and beyond.
• MPP debottlenecking at Dahej commissioned in September 2026 — will drive specialty growth beyond current levels and is not yet factored into numbers; MPP1 and MPP2 to "far exceed" par by end of FY 2026-2027.
• CDMO momentum strong with the FY27 target well within reach — growth from the base Fermion business and encouraging new qualification campaigns; deepening engagement with a leading European CDMO major; portfolio spans oncology, cardiovascular, neurology and animal health.
• Ref gas placed at better-than-average prices — management said judging ref gas upside by industry averages "would not be a fair statement."

Contract Extension to December 2032 Rebutted the Erosion Thesis

• Solstice Advanced Materials contract extended by 4 years until December 2032 — additional revenue potential of approximately US$180 million; CFO said it adds leverage from the same assets and provides visibility beyond FY28.
• CFO rebutted the $45mn vs $58mn run-rate read — pricing is a pass-through mechanism (with different economics once capex is recovered), so the analyst's implied annual run-rate is "a simplistic read"; the contract will guarantee larger volumes than before.
• Extension converts a 7-year contract into an 11-year contract — addressing the Honeywell contract question after 2028 and protecting the base underpinning growth discussed between now and FY30; pricing for the current contract was set in 2020, a different environment from today's and from what will prevail in 2028.
• Patent-expiry price-erosion thesis rebutted — each HFO serves a distinct end application and the patent owner also covers a qualification route, so refrigerant market dynamics do not directly apply; Solstice has indicated its product is an "evergreen product" in terms of end-use application.
• Global HFO capacity currently stands at 10% of global ref demand in tonnage terms — per the CFO, insufficient volume for players to compete on pricing in that market; HFOs command a pricing premium as greener, cleaner products.
• Own HFO commercialization not blocked by the Honeywell contract — the company will not enter the same application covered by the contract, but with 40 different HFO varieties nothing prevents other HFO work; both partnership and product models will be evaluated.

$100mn Visibility Target in Sight; CGMP4 Phase 2 by Q4 FY27

• "Striking distance" of the $100 million CDMO order book visibility target by end of FY 2026-2027 — management said reaching it on a run-rate basis is "on time," not early, as the target has always been for FY27.
• CGMP4 phase 2 capex of approximately Rs.125 crore expected operational by end of Q4 FY27 — with phase 1 and 2 combined, peak annual revenue potential close to 3x capital deployed, or about Rs.900-1,000 crore, by FY29 (speaker self-corrected mid-answer from FY28); both phases "completely dedicated" to Fermion.
• CGMP5 can move "pretty quickly" — warehouse built up to Phase 6 and ETP up to Phase 5; management committed to triggering Phase 5 as soon as CGMP plant utilization reaches 70-80% (event-based trigger, period unspecified).
• Of 10 CDMO molecules in development, 2 showing "very encouraging" progress — 3 expected to reach a readout within 8-12 months as guided on the previous call; one molecule approved in China and on fast track for US FDA approval; second molecule's upside is a potential label expansion of darolutamide.
• Five new spec chem molecules under development with campaign orders running to end of FY 2026-2027 and beyond — management constructive on long-term agri demand but will extract more from current assets rather than add capacity; a new MPP is a "hypothetical question at this stage."
• Growth to FY28 "pretty much baked in" with capex already in place — some portion (CGMP4) extending into FY29; pipeline described as "healthy and rich"; on the analyst's Rs.1,200-1,300 crore proposal, growth beyond FY27 to that level is "not unimaginable" — hedged, not a commitment.

Camode Delay Is "a Conscious Choice"; DRDO On Track

• Chemours qualified its product earlier in FY 2026-2027 with French OEM 2CRSI — a manufacturer of high-compute kits with 1U architecture, under a joint development agreement; management called the development "very encouraging" and noted anyone establishing hypercomputing environments is likely to use OEMs to qualify materials.
• Chemours commissioning delay described as "a conscious choice" — attributed to finalizing the right process route for initial capacity, which then allows accelerating the larger capacity should demand materialize; Navin has purchase orders in hand from Chemours for future quarters.
• About 15 months needed once the Camode project is commissioned — to know the market adoption rate, market size and hence the capex; premature to discuss final eventual capex, and specifics are under NDA ("more a Chemours conversation than a Navin conversation").
• DRDO contract on track, working to the prescribed schedule — the molecule is dual-use; the pharma application will be accelerated once developed, ahead of the longer defense qualification timeline; even at 50%, the Indian pharma market for the molecule is roughly Rs.400 crore (period unspecified).
• Advanced materials capacity investment on schedule to commission by Q2 FY28 — targeting data centers, electronics, semiconductors and defense; expected to be roughly 10-15% of an expanded revenue pie by 2030 in the scenario where Navin grows 20-25% from now to 2030, framed as "a milestone rather than the end of the journey."

Rs.700-1,000 Crore Annual Frame; 30% Long-Term Margin Guidance Unchanged

• Annual capex frame of Rs.700-1,000 crore every year — CFO corrected the analyst's Rs.750 crore framing as a range, not a fixed figure; FY 2026-2027 capex guided at Rs.700 crore with H1 spend at ~Rs.300-310 crore, on track for the lower end; FY 2027-2028 capex to be announced toward the end of FY 2026-2027 via stage-gate approvals.
• Frame underpinned by a strong balance sheet — working capital held at 70-75 days and EBITDA conversion of 60%, moving toward 65% on a more sustainable basis; sized to fund the project hopper and growth targeted over the next 5 years.
• Long-term EBITDA margin guidance unchanged at 30% — CFO declined to predict margins 5-6 years out citing "massively volatile" geopolitics; for FY27, full-year margins to be worked toward in the same range as H1 FY27 levels.
• HFC capacity expansion on track for commissioning shortly — the new 32 HPP plant will ramp up toward end of Q3 FY 2026-2027 with full ramp-up possibly in Q4 FY 2026-2027; no significant shift away from the HFC business foreseen over the next three-odd years.
• CMOS project progressing towards commissioning in Q3 FY27 — enabling participation in the emerging advanced cooling market; TDAF project with DRDO progressing as per schedule.
• HFO plant utilization to improve as volumes rise across two end applications — construction (tied to the global market scenario improving over time) and chillers for high cooling; indicated volumes reflect only minimum expected quantities from the customer; renewable energy to meet more than 60% of energy requirement (period unspecified).
• No explicit commitment made on distributing surplus free cash flow to shareholders.